Last reviewed · How we verify
NCT04258137: COPE
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
NA trial testing Liquid biopsy in Colorectal Cancer in 332 participants. Currently enrolling.
1 December 2026
Quick facts
| Lead sponsor | Institut Bergonié |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 332 |
| Start date | 4 September 2020 |
| Primary completion | 1 December 2026 |
| Estimated completion | 1 December 2027 |
| Sites | 6 locations across France |
Drugs / interventions tested
- Liquid biopsy — full drug profile →
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
Sponsor
Institut Bergonié — full company profile →
Who can join
18 and older, any sex, with Colorectal Cancer or Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
COPE is a biology driven protocol with 2 independent, multicentric, two-arm non-comparative randomized (2:1) phase II trials in 2 distinct populations: colorectal cancer patients and non-small-lung cancer patients. For each phase II trial, patient will be randomized between two arms with two patients randomized in arm A for one patient randomized in arm B: * Arm A (Experimental - initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up combining standard imaging and ctDNA analysis) * Arm B (Standard - initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up based on standard imaging).
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Molecular subtypes of colorectal cancer in the era of precision oncotherapy: Current inspirations and future challenges.
Dang Q, Zuo L, Hu X, Zhou Z, et al · · 2024 · cited 9× · PMID 39054866 · DOI 10.1002/cam4.70041 -
The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer.
Bożyk A, Nicoś M. · · 2022 · cited 6× · PMID 36295075 · DOI 10.3390/life12101640 -
Liquid Biopsies in the Early Diagnosis, Prognosis, and Tailored Treatment of Colorectal Cancer.
Liatsou E, Kollias I, Trapali M, Tsilimigras DI, et al · · 2025 · cited 4× · PMID 40149264 · DOI 10.3390/cancers17060927 -
Clinical Applications of Liquid Biopsy in Non-Small Cell Lung Cancer Patients: Current Status and Recent Advances in Clinical Practice.
Park S, Lee JC, Choi CM. · · 2021 · cited 2× · PMID 34064038 · DOI 10.3390/jcm10112236
Verify or expand the search:
- PubMed search for NCT04258137
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Liquid biopsy
Trials testing the same drug.
- NCT06605443 — Precision Medicine for L/GCMN and Melanoma 2 · recruiting
- NCT06283576 — Pancreatic Cancer Initial Detection Via Liquid Biopsy · enrolling by invitation
- NCT06592716 — Can Recurrence of Cancer in the Oropharynx be Detected by Blood Samples? · active not recruiting
- NCT07418125 — Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA · NA · recruiting
- NCT06605417 — Understanding the Transition from Normal Melanocytes to Nevus to Melanoma · recruiting
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Institut Bergonié trials
Trials by the same sponsor.
- NCT06084689 — Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures · Phase 2 · withdrawn
- NCT06700057 — Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer. · recruiting
- NCT05690828 — Evaluation of Cognitive Management for Chemobrain in Patients Treated for Breast Cancer. · NA · active not recruiting
- NCT05415527 — Evaluation of Pretreatment Sarcopenia in Patients With Inoperable High-grade Ovarian Carcinoma as Part of Optimised Mana · NA · active not recruiting
- NCT04912687 — Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04258137 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut Bergonié
- Last refreshed: 2 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04258137.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing